13F filer · CIK 1652044 ↗
Alphabet Inc.
Reported value
$99.08B
+2,367% on the quarter before
Positions
28
3 new · 1 sold out
Top 10
99.5%
of the value
Est. gain
+$746.7M
on stocks held all quarter
Est. return
+18.8%
on those stocks since Q1 2026
Positions as of Jun 30, 2026, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2026. Striped tiles are options.
Largest buys
Since Q1 2026, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- SpaceX~$94.18BNew · 0.0% → 95.0%+551,189,500 shares
- Parabilis Medicines Inc~$134.6MNew · 0.0% → 0.1%+4,919,498 shares
- Fervo Energy Co~$51.5MNew · 0.0% → 0.1%+1,760,732 shares
Largest sells
Since Q1 2026, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Revolution Medicines Inc~$64.8MCut · 8.0% → 0.6%−345,906 shares
- Monte Rosa Therapeutics Inc~$7.5MCut · 0.3% → 0.0%−311,801 shares
- Relay Therapeutics Inc~$2.9MCut · 0.4% → 0.0%−154,144 shares
- Ethos Technologies Inc~$2.7MCut · 1.0% → 0.1%−147,552 shares
- Tenaya Therapeutics Inc~$631,836Sold out · 0.0% → 0.0%−915,705 shares
Holdings
As of Jun 30, 2026. Changes are in shares against Mar 31, 2026, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SpaceXCLASS A COM STK · shares New | 95.0% | $94.18B | — | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price +18.5% | 1.2% | $1.17B | +$182.6M | ||||||||
| AST SpaceMobileCOM CL A · shares 0% · price +7.2% | 0.80% | $794.7M | +$53.6M | ||||||||
| CME GroupCOM · shares 0% · price −25.2% | 0.78% | $769.4M | −$259.6M | ||||||||
| ArmSPONSORED ADS · shares 0% · price +134.4% | 0.70% | $695.2M | +$398.6M | ||||||||
| Revolution Medicines IncCOM · shares −11% · price +92.6% | 0.56% | $551.8M | +$265.3M | ||||||||
| FreshworksCLASS A COM · shares 0% · price +26.0% | 0.17% | $164.0M | +$33.9M | ||||||||
| Parabilis Medicines IncCOM · shares New | 0.14% | $134.6M | — | ||||||||
| Tempus AICL A · shares 0% · price +28.1% | 0.09% | $89.9M | +$19.7M | ||||||||
| GitLabCLASS A COM · shares 0% · price +41.1% | 0.08% | $83.2M | +$24.2M | ||||||||
| UiPathCL A · shares 0% · price −2.1% | 0.08% | $76.5M | −$1.6M | ||||||||
| Ethos Technologies IncCL A · shares −3.9% · price +62.4% | 0.07% | $65.7M | +$25.2M | ||||||||
| Prime Medicine IncCOM · shares 0% · price +6.0% | 0.06% | $61.1M | +$3.5M | ||||||||
| Fervo Energy CoCL A COM · shares New | 0.05% | $51.5M | — | ||||||||
| PayPay CorporationSPONSORED ADS · shares 0% · price −32.8% | 0.05% | $44.8M | −$21.9M | ||||||||
| Maze Therapeutics IncCOM · shares 0% · price −0.0% | 0.04% | $41.4M | −$13,886 | ||||||||
| Relay Therapeutics IncCOM · shares −9.9% · price +88.0% | 0.03% | $26.4M | +$12.4M | ||||||||
| Bridgebio Oncology TherapeutCOM NEW · shares 0% · price −14.9% | 0.02% | $21.5M | −$3.8M | ||||||||
| Oscar Health IncCL A · shares 0% · price +148.6% | 0.01% | $13.7M | +$8.2M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price +44.0% | 0.01% | $11.0M | +$3.4M | ||||||||
| Vera Therapeutics IncCL A · shares 0% · price +6.7% | 0.01% | $10.4M | +$646,587 | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price +21.2% | 0.01% | $9.8M | +$1.7M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares −46% · price +47.1% | 0.01% | $9.0M | +$2.9M | ||||||||
| Lyell Immunopharma IncCOM NEW · shares 0% · price −30.0% | 0.00% | $4.1M | −$1.8M | ||||||||
| FigmaCLASS A COM STK · shares 0% · price −14.4% | 0.00% | $3.9M | −$657,525 | ||||||||
| Total · 28 positions | 100% | $99.08B | +$746.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2026 to Q2 2026: 25 stocks held throughout, up $746.7M (+18.8%).
- Arm+$398.6M+134%
- Revolution Medicines Inc+$265.3M+93%
- Planet Labs Pbc+$182.6M+19%
- AST SpaceMobile+$53.6M+7%
- Freshworks+$33.9M+26%
- UiPath−$1.6M−2%
- Lyell Immunopharma Inc−$1.8M−30%
- Bridgebio Oncology Therapeut−$3.8M−15%
- PayPay Corporation−$21.9M−33%
- CME Group−$259.6M−25%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |